Emerging options for the treatment of melanoma – focus on ipilimumab
Claire Roddie, Karl S Peggs UCL Cancer Institute, Department of Hematology, London, UK Abstract: Ipilimumab is a fully human immunoglobulin subclass G1 anticytotoxic-T-lymphocyte-antigen-4 monoclonal antibody. It has been approved by the US Food and Drug Administration (FDA) and the European Medici...
Gardado en:
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2014-03-01
|
| Series: | ImmunoTargets and Therapy |
| Assuntos: | |
| Acceso en liña: | https://www.dovepress.com/emerging-options-for-the-treatment-of-melanoma-ndash-focus-on-ipilimum-peer-reviewed-article-ITT |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|